HK1149709A1 - Use of mva to treat prostate cancer mva - Google Patents

Use of mva to treat prostate cancer mva

Info

Publication number
HK1149709A1
HK1149709A1 HK11103921.5A HK11103921A HK1149709A1 HK 1149709 A1 HK1149709 A1 HK 1149709A1 HK 11103921 A HK11103921 A HK 11103921A HK 1149709 A1 HK1149709 A1 HK 1149709A1
Authority
HK
Hong Kong
Prior art keywords
mva
prostate cancer
treat prostate
recombinant mva
mva viruses
Prior art date
Application number
HK11103921.5A
Inventor
Alain Delcayre
Reiner Laus
Stefanie Mandl
Ryan Blair Rountree
Fatema Legrand
Original Assignee
Bavarian Nordic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic Inc filed Critical Bavarian Nordic Inc
Publication of HK1149709A1 publication Critical patent/HK1149709A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Abstract

The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
HK11103921.5A 2007-10-18 2011-04-19 Use of mva to treat prostate cancer mva HK1149709A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96089307P 2007-10-18 2007-10-18
PCT/US2008/080229 WO2009052328A1 (en) 2007-10-18 2008-10-16 Use of mva to treat prostate cancer

Publications (1)

Publication Number Publication Date
HK1149709A1 true HK1149709A1 (en) 2011-10-14

Family

ID=40342626

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103921.5A HK1149709A1 (en) 2007-10-18 2011-04-19 Use of mva to treat prostate cancer mva

Country Status (14)

Country Link
US (2) US7867483B2 (en)
EP (1) EP2207564B1 (en)
JP (1) JP5669581B2 (en)
KR (2) KR20160065985A (en)
CN (1) CN101888853B (en)
AU (1) AU2008312444B2 (en)
CA (1) CA2702586C (en)
DK (1) DK2207564T3 (en)
ES (1) ES2608604T3 (en)
HK (1) HK1149709A1 (en)
IL (1) IL204541A (en)
NZ (2) NZ584042A (en)
RU (1) RU2499606C2 (en)
WO (1) WO2009052328A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
ES2256323T5 (en) * 2000-11-23 2016-11-21 Bavarian Nordic A/S Variant of the Modified Vaccinia Ankara virus
ES2363891T3 (en) 2006-03-20 2011-08-18 The Regents Of The University Of California ANTIBODIES AGAINST THE ANTIGEN OF TRONCAL CELLS OF THE PROSTATE (PSCA) GENETICALLY MODIFIED FOR ADDRESSING TO CANCER.
WO2009032949A2 (en) * 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
JP5951929B2 (en) * 2007-10-03 2016-07-13 コーネル ユニヴァーシティー Treatment of proliferative disorders using PSMA antibodies
DK2207564T3 (en) * 2007-10-18 2017-01-16 Bavarian Nordic As USE OF VAT FOR TREATMENT OF PROSTATACANCES
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
CA2752510C (en) * 2009-02-17 2024-01-23 Neil Bander Methods and kits for diagnosis of cancer and prediction of therapeutic value
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
BR112012012887A2 (en) 2009-12-02 2017-05-02 Imaginab Inc nucleotide sequence-coded minibody and cys-diabody (cysdb), their use and methods for diagnosing and treating cancer associated with psma expression in a subject.
JP6312141B2 (en) 2012-03-30 2018-04-18 国立大学法人京都大学 Urinary biomarker for prostate cancer test
MY182168A (en) 2013-11-01 2021-01-18 Pfizer Vectors for expression of prostate-associated antigens
KR20170083534A (en) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 Chimeric antigen receptors
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN116173193A (en) 2015-04-17 2023-05-30 纪念斯隆凯特琳癌症中心 Use of MVA or MVA delta E3L as immunotherapeutic agent against solid tumors
EP4137158A1 (en) 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
FR3042121A1 (en) 2015-10-08 2017-04-14 Jean-Marc Limacher ANTI-TUMOR COMPOSITION
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3413927A4 (en) * 2016-02-12 2019-11-27 Madison Vaccines Inc. Cancer therapy
EP3419662A4 (en) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CN109152815B (en) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 Replication-competent attenuated vaccinia virus with thymidine kinase deletion and with or without human FLT3L or GM-CSF expression for cancer immunotherapy
TWI746545B (en) * 2016-04-26 2021-11-21 日商大日本住友製藥股份有限公司 Substituted purine derivative
RU2753585C2 (en) 2016-06-03 2021-08-18 Регенерон Фармасьютикалз, Инк. Non-human animals expressing exogenous terminal deoxynucleotidyl transferase
SG11201810631SA (en) * 2016-06-03 2018-12-28 Etubics Corp Compositions and methods for tumor vaccination using prostate cancer-associated antigens
CN106119231A (en) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 The CTL of a kind of tumor antigen PSA identifies epitope peptide and application thereof
CN106084027A (en) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 The CTL of specific tumor antigen EphA2 identifies epitope peptide and application thereof
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
WO2020247859A2 (en) * 2019-06-07 2020-12-10 Oregon Health & Science University Tumor-associated antigen-specific t cell responses
WO2021209897A1 (en) * 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2022009052A2 (en) * 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001831A1 (en) * 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
US5925362A (en) * 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
EP0951541B1 (en) * 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
JP2001516226A (en) * 1997-04-11 2001-09-25 デンドレオン コーポレイション Compositions and methods for inducing an immune response to tumor-associated antigens
EA003634B1 (en) * 1998-10-05 2003-08-28 Фармэкса А/С Novel methods for therapeutic vaccination
CA2354024C (en) * 1998-12-09 2009-12-22 Jeffrey Schlom A recombinant vector expressing multiple costimulatory molecules and uses thereof
ES2256323T5 (en) * 2000-11-23 2016-11-21 Bavarian Nordic A/S Variant of the Modified Vaccinia Ankara virus
AU2003219983A1 (en) * 2002-03-01 2003-09-16 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
EA020230B1 (en) * 2002-05-16 2014-09-30 Бавариан Нордик А/С Recombinant modified vaccinia ankara (mva) poxvirus, expressing homologous sequences introduced into poxvirus genome and use thereof
NZ545438A (en) * 2003-08-21 2008-08-29 Virax Dev Pty Ltd Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
BRPI0401465A (en) 2004-04-20 2006-02-21 Embria Informatica Ltda system for managing interactions between users and software applications in a web environment
DK2207564T3 (en) * 2007-10-18 2017-01-16 Bavarian Nordic As USE OF VAT FOR TREATMENT OF PROSTATACANCES

Also Published As

Publication number Publication date
WO2009052328A8 (en) 2009-07-02
DK2207564T3 (en) 2017-01-16
JP2011500718A (en) 2011-01-06
US8377688B2 (en) 2013-02-19
EP2207564A1 (en) 2010-07-21
US20110008386A1 (en) 2011-01-13
RU2499606C2 (en) 2013-11-27
JP5669581B2 (en) 2015-02-12
CA2702586C (en) 2017-08-01
CA2702586A1 (en) 2009-04-23
US20090104225A1 (en) 2009-04-23
CN101888853B (en) 2013-03-13
US7867483B2 (en) 2011-01-11
IL204541A0 (en) 2010-11-30
WO2009052328A1 (en) 2009-04-23
NZ601827A (en) 2014-01-31
IL204541A (en) 2015-02-26
AU2008312444A1 (en) 2009-04-23
KR20100109545A (en) 2010-10-08
CN101888853A (en) 2010-11-17
KR20160065985A (en) 2016-06-09
RU2010115220A (en) 2011-11-27
AU2008312444B2 (en) 2014-02-06
KR101648087B1 (en) 2016-08-17
NZ584042A (en) 2012-09-28
EP2207564B1 (en) 2016-10-05
ES2608604T3 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
HK1149709A1 (en) Use of mva to treat prostate cancer mva
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
WO2008045346A3 (en) Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
MX2016004551A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis.
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
EA201000016A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND DISTURBANCES ASSOCIATED WITH TUMORS
MX341076B (en) Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments.
NZ606195A (en) Methods and compositions for liver cancer therapy
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2007053573A3 (en) Treatment of cancer with sorafenib
MX2011010390A (en) Polymer-agent conjugates, particles, compositions, and related methods of use.
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
MX2009008132A (en) Combination therapy with angiogenesis inhibitors.
MX346924B (en) Diarylhydantoin compounds.
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
MY191825A (en) Therapeutic compounds and compositions
MY162903A (en) Methods of treatment of pancreatic cancer
MX342274B (en) Therapeutic compounds and compositions.
MX2007011545A (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors.
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
MX2009009761A (en) Compositions and kits for treating influenza.
WO2008030883A3 (en) Treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191010